116 related articles for article (PubMed ID: 12415619)
1. In vivo advantage of combined administration with CPT-11 and 5-fluorouracil in rats.
Satoh H; Ohtomo M; Ishikawa H; Kamma H; Yamashita YT; Ohtsuka M; Sekizawa K
J Exp Ther Oncol; 2002; 2(1):42-6. PubMed ID: 12415619
[TBL] [Abstract][Full Text] [Related]
2. Adding weekly irinotecan to high-dose 5-fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer--a phase II study.
Hofheinz R; Hartung G; Samel S; Emig M; Pilz L; Willeke F; Hochhaus A; Hehlmann R; Queisser W
Anticancer Drugs; 2002 Nov; 13(10):999-1004. PubMed ID: 12439333
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effect of combined administration with CPT-11 and 5-fluorouracil in vitro and in vivo.
Satoh H; Ohtomo M; Ishikawa H; Kamma H; Ohtsuka M; Hasegawa S
Cancer Biochem Biophys; 1999 Jul; 17(1-2):59-67. PubMed ID: 10738902
[TBL] [Abstract][Full Text] [Related]
4. Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines.
Mans DR; Grivicich I; Peters GJ; Schwartsmann G
Eur J Cancer; 1999 Dec; 35(13):1851-61. PubMed ID: 10674003
[TBL] [Abstract][Full Text] [Related]
5. A phase I, dose-finding study of irinotecan (CPT-11) short i.v. infusion combined with fixed dose of 5-fluorouracil (5-FU) protracted i.v. infusion in adult patients with advanced solid tumours.
Sastre J; Paz-Ares L; Carcas A; Alfonso R; Grávalos C; Frías J; Guerra P; Pronk L; Cortés-Funes H; Díaz-Rubio E
Cancer Chemother Pharmacol; 2005 May; 55(5):453-60. PubMed ID: 15818508
[TBL] [Abstract][Full Text] [Related]
6. Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase.
Fukushima M; Sakamoto K; Ohshimo H; Nakagawa F; Taguchi T
Oncol Rep; 2010 Oct; 24(4):835-42. PubMed ID: 20811661
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of the combination of oxaliplatin, irinotecan and continuous infusion 5-fluorouracil in digestive tumors.
Abad A; Massutí B; Gallego J; Yuste AL; Manzano JL; Carrato A; Antón A; Marfa X; Diaz-Rubio E;
Anticancer Drugs; 2004 Jun; 15(5):469-71. PubMed ID: 15166620
[TBL] [Abstract][Full Text] [Related]
8. Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose.
Cao S; Rustum YM
Cancer Res; 2000 Jul; 60(14):3717-21. PubMed ID: 10919639
[TBL] [Abstract][Full Text] [Related]
9. Schedule-dependent cytotoxicity of 5-fluorouracil and irinotecan in a colon cancer cell line.
Inoue Y; Miki C; Watanabe H; Hiro J; Toiyama Y; Ojima E; Yanagi H; Kusunoki M
J Gastroenterol; 2006 Dec; 41(12):1149-57. PubMed ID: 17287894
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors.
Goetz MP; Erlichman C; Windebank AJ; Reid JM; Sloan JA; Atherton P; Adjei AA; Rubin J; Pitot H; Galanis E; Ames MM; Goldberg RM
J Clin Oncol; 2003 Oct; 21(20):3761-9. PubMed ID: 12963697
[TBL] [Abstract][Full Text] [Related]
11. Schedule-dependent cytotoxicity of 5-fluorouracil and irinotecan in p53 mutant human colon cancer.
Tanaka K; Inoue Y; Hiro J; Yoshiyama S; Toiyama Y; Eguchi T; Miki C; Kusunoki M
J Exp Clin Cancer Res; 2007 Jun; 26(2):241-51. PubMed ID: 17725105
[TBL] [Abstract][Full Text] [Related]
12. A dose-finding study of irinotecan (CPT-11) plus a four-day continuous 5-fluorouracil infusion in advanced colorectal cancer.
Kakolyris S; Souglakos J; Kouroussis C; Androulakis N; Mavroudis D; Kalbakis K; Kotsakis A; Vardakis N; Koukourakis M; Romanos J; Georgoulias V
Oncology; 2001; 60(3):207-13. PubMed ID: 11340371
[TBL] [Abstract][Full Text] [Related]
13. CPT-11 (irinotecan) and 5-fluorouracil: a promising combination for therapy of colorectal cancer.
Saltz L; Shimada Y; Khayat D
Eur J Cancer; 1996; 32A Suppl 3():S24-31. PubMed ID: 8943662
[TBL] [Abstract][Full Text] [Related]
14. Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy.
Nobili S; Checcacci D; Filippelli F; Del Buono S; Mazzocchi V; Mazzei T; Mini E
J Chemother; 2008 Oct; 20(5):622-31. PubMed ID: 19028627
[TBL] [Abstract][Full Text] [Related]
15. A phase I pharmacologic and pharmacogenetic trial of sequential 24-hour infusion of irinotecan followed by leucovorin and a 48-hour infusion of fluorouracil in adult patients with solid tumors.
Wright MA; Morrison G; Lin P; Leonard GD; Nguyen D; Guo X; Szabo E; Hopkins JL; Leguizamo JP; Harold N; Fioravanti S; Schuler B; Monahan BP; Saif MW; Quinn MG; Pang J; Grem JL
Clin Cancer Res; 2005 Jun; 11(11):4144-50. PubMed ID: 15930350
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of CPT-11 and bolus 5-FU/ l-leucovorin in patients with metastatic colorectal cancer.
Fujishima H; Kikuchi I; Miyanaga O; Ueda A; Baba E; Mitsugi K; Harada M; Nakano S
Int J Clin Oncol; 2004 Apr; 9(2):92-7. PubMed ID: 15108040
[TBL] [Abstract][Full Text] [Related]
17. Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer.
Fioravanti A; Canu B; Alì G; Orlandi P; Allegrini G; Di Desidero T; Emmenegger U; Fontanini G; Danesi R; Del Tacca M; Falcone A; Bocci G
Eur J Pharmacol; 2009 Oct; 619(1-3):8-14. PubMed ID: 19695243
[TBL] [Abstract][Full Text] [Related]
18. Sequential administration of 5-fluorouracil (5FU)/leucovorin (LV) followed by irinotecan (CPT-11) at relapse versus CPT-11 followed by 5-FU/LV in advanced colorectal carcinoma. A phase III randomized study.
Tsavaris N; Kosmas C; Skopelitis H; Papadoniou N; Polyzos A; Zografos G; Adoniou E; Gryniatsos J; Felekouras E; Zacharakis M; Sigala F; Bacoyiannis C; Papastratis G; Papalambros E
Chemotherapy; 2007; 53(4):282-91. PubMed ID: 17496414
[TBL] [Abstract][Full Text] [Related]
19. Irinotecan (CPT-11) in combination with infusional 5-fluorouracil and leucovorin (de Gramont regimen) as first-line treatment in patients with advanced colorectal cancer: a multicenter phase II study.
Vamvakas L; Kakolyris S; Kouroussis C; Kandilis K; Mavroudis D; Ziras N; Androulakis N; Kalbakis K; Sarra E; Souglakos J; Georgoulias V;
Am J Clin Oncol; 2002 Feb; 25(1):65-70. PubMed ID: 11823700
[TBL] [Abstract][Full Text] [Related]
20. Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer.
Ducreux M; Ychou M; Seitz JF; Bonnay M; Bexon A; Armand JP; Mahjoubi M; Méry-Mignard D; Rougier P
J Clin Oncol; 1999 Sep; 17(9):2901-8. PubMed ID: 10561369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
